Evidence map›Paper›PMID 28493225›Full record

ReviewSchmerz (Berlin, Germany)2017

[Definition, diagnostics and therapy of chronic widespread pain and the (so-called) fibromyalgia syndrome in children and adolescents : Updated guidelines 2017].

N Draheim, F Ebinger, E Schnöbel-Müller, B Wolf, W Häuser

Abstract readReview
PubMed Publisher
In one paragraph

Review in Schmerz (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 8 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 8 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Review
  10. Article
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Facts and myths pertaining to fibromyalgia.Dialogues in clinical neuroscience · 2018
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

N DraheimZentrum für Schmerztherapie junger Menschen, Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Deutschland. draheim.nicole@rheuma-kinderklinik.de.
F EbingerKlinik für Kinder- und Jugendmedizin, St. Vincenz-Krankenhaus Paderborn, Paderborn, Deutschland.
E Schnöbel-MüllerZentrum für Schmerztherapie junger Menschen, Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Deutschland.
B WolfDeutsche Fibromyalgie Vereinigung, Seckach, Deutschland.
W HäuserInnere Medizin I, Klinikum Saarbrücken gGmbH, Saarbrücken, Deutschland.
Brüderkrankenhaus St. Josef Paderborn · DEGerman Center for Pediatric and Adolescent Rheumatology · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was scheduled for April 2017.

methodsThe guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n = 8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest. A search of the literature for case series (cross-sectional- and longitudinal studies) for the topics diagnosis, etiology and pathophysiology and for randomised controlled trials (RCT) for treatment modalities from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of available therapies were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines. RESULTS AND

conclusionNo consensus was achieved in the guideline group on whether the diagnostic label "juvenile fibromyalgia" should be used in the management of children and adolescents with chronic widespread pain. There was consensus in the guideline group that antidepressants and anticonvulsants should not be used to treat pain in the so-called juvenile fibromyalgia syndrome.

Indexed as

Practice Guidelines as TopicAdolescentChildCombined Modality TherapyConsensus Statements as TopicEvidence-Based MedicineFibromyalgiaGermanyHumansPain ManagementPatient PreferenceRandomized Controlled Trials as TopicRisk AssessmentSocieties, MedicalTreatment OutcomeChildren and adolescentsChronic pain disorder with somatic and psychological factorsGuidelinesJuvenile fibromyalgia syndromeReview, systematic

Identifiers

PMID28493225
OpenAlexW1589422868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.